Skip to main content
Clinical Trials/EUCTR2012-000291-42-ES
EUCTR2012-000291-42-ES
Active, not recruiting
Phase 1

Effect of treatment with testosterone undecaonat in patients with Diabetes Mellitus Type 1 (DM-1) and hipogonadotrophic hypogonadism

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar)
Status
Active, not recruiting
Last Updated
9 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 23, 2012
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
Male

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Men older than or equal to 18\.
  • 2\. Submit a diagnosis of diabetes mellitus type 1 and hypogonadotropic hypogonadism, defined as:
  • ? Levels of total testosterone \<8nmol / L(2\.3 ng/mL), or total testosterone levels between 8 and 12 nmol / L (2\.3\-3\.5 ng/mL)and calculated free testosterone \<225 pmol / L (65 pg / mL).
  • ? Determination of LH below 8\.6 mU / mL and / or FSH lower than 14\.2 IU / L.
  • 3\. Being able to provide informed consent before randomization and agree to abide by the study protocol.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 14
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • 1\. Existence of chronic debilitating disease such as kidney failure, cirrhosis, HIV, COPD, heart failure, ischemic heart disease.
  • 2\. Patients with hypergonadotropic hypogonadism.
  • 3\. Patients diagnosed with panhypopituitarism.
  • 4\. Patients with hypogonadotropic hypogonadism secondary to pituitary tumor or empty sella.
  • 5\. Patients with hypogonadotropic hypogonadism secondary to hyperprolactinemia.
  • 6\. Patients with contraindications to the administration of testosterone: elevated PSA, breast carcinoma, prostate carcinoma, liver tumors
  • 7\. Patients previously treated with testosterona
  • 8\. Patients with allergy to testosterone and/or excipients.

Outcomes

Primary Outcomes

Not specified

Similar Trials